A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need

Quantitative systems pharmacology (QSP) is a rapidly emerging discipline with application across a spectrum of challenges facing the pharmaceutical industry, including mechanistically informed prioritization of target pathways and combinations in discovery, target population, and dose expansion decisions early in clinical development, and analyses for regulatory authorities late in clinical development. QSP's development has influences from physiologic modeling, systems biology, physiologically‐based pharmacokinetic modeling, and pharmacometrics. Given a varied scientific heritage, a variety of tools to accomplish the demands of model development, application, and model‐based analysis of available data have been developed. We report the outcome from a community survey and resulting analysis of how modelers view the impact and growth of QSP, how they utilize existing tools, and capabilities they need improved to further accelerate their impact on drug development. These results serve as a benchmark and roadmap for advancements to the QSP tool set.

[1]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[2]  Jacky L. Snoep,et al.  BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems , 2005, Nucleic Acids Res..

[3]  J Chard,et al.  Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model-Based Drug Development , 2013, CPT: pharmacometrics & systems pharmacology.

[4]  Tove Tuntland,et al.  Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..

[5]  Arijit Chakravarty,et al.  Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape , 2014, The AAPS Journal.

[6]  K Biliouris,et al.  MatVPC: A User-Friendly MATLAB-Based Tool for the Simulation and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.

[7]  Hiroaki Kitano,et al.  Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. , 2003, Omics : a journal of integrative biology.

[8]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[9]  Mary Goldman,et al.  Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.

[10]  Manish Gupta,et al.  QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models , 2017, The AAPS Journal.

[11]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[12]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[13]  R J Allen,et al.  Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models , 2015, bioRxiv.

[14]  Albert Wang,et al.  Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..

[15]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[16]  Marc R. Gastonguay,et al.  Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve , 2015 .

[17]  Johan Gabrielsson,et al.  Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.

[18]  Hiroaki Kitano,et al.  The ERATO Systems Biology Workbench: Enabling Interaction and Exchange Between Software Tools for Computational Biology , 2001, Pacific Symposium on Biocomputing.

[19]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[20]  MN Trame,et al.  Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.

[21]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[22]  David J. Klinke,et al.  Integrating Epidemiological Data into a Mechanistic Model of Type 2 Diabetes: Validating the Prevalence of Virtual Patients , 2008, Annals of Biomedical Engineering.

[23]  J Wojciechowski,et al.  Interactive Pharmacometric Applications Using R and the Shiny Package , 2015, CPT: pharmacometrics & systems pharmacology.

[24]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[25]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[26]  K Gadkar,et al.  The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non‐obese diabetic mouse , 2010, Clinical and experimental immunology.

[27]  White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation , 2013, CPT: pharmacometrics & systems pharmacology.

[28]  Nail M. Gizzatkulov,et al.  DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results , 2010, BMC Systems Biology.

[29]  Fan Wu,et al.  Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape , 2018, CPT: pharmacometrics & systems pharmacology.

[30]  Fergal P. Casey,et al.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.

[31]  H. S. Lee,et al.  Nutrient intake and urinary incontinence in Korean women: A propensity score‐matched analysis from the Korea National Health and Nutrition Examination Survey data , 2017, International journal of urology : official journal of the Japanese Urological Association.

[32]  Edward W. Lowe,et al.  Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.